Cancer
Conditions
Interventions
genome, pharmacokinetics, proteome and metaborome
Sponsors
Saitama Medical University, International Medical Center, Department of Medical Oncology
Showa University, School of Medicine, Division of Respiratory and Allergy Department of Internal Medicine Keio University, School of Medicine, Department of Pharmacy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with histologically confirmed solid tumors. 2)Patients who are 20 years or higher. 3)Patients with ECOG performance status of 0 to 3. 4)Patients who are expected to live at least 2 months or more. 5)Patients with measurable and evaluable lesion(s). 6)Patients never treated with the target anticancer drug(s). No history of chemotherapy or within 3 weeks. 7)Blood tests 1. Neutrophile count 2000 /mm3 or higher. 2. Platelet count 100,000 /mm3 or higher. 3. Hemoglobin 9.0 g/dL or higher. 4. AST, ALT less than 2.0 times the upper limit of normal. 5. Total bilirubin 2.0 mg/dL or less. 6. Serum creatinine 1.5 mg/dLor less. 8)All patients were asked for written informed consent for their peripheral blood samples and medical information to be used for research purposes.
Exclusion criteria
Exclusion criteria: 1)Patients with interstitial pneumonia or pulmonary fibrosis. 2)Patients with severe infection (with fever). 3)Patients with incontrollable diabetes. 4)Patients with severe heart failure. 5)Patients with severe complication such as cirrhosis. 6)Patients with mental or nerve disorder. 7)Pregnant patients or patients giving the breast. Men and wemen who want to make baby. 8)Patients with severe allergy or those who had severe allergy in the past. 9)Patients who are contraindication for cancer chamotherapy. 10)Patients hypersensitive to the anticancer drug(s). 11)Patients who are not appropriate to participate in the study safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genetic polymorphisms in factors associated with pharmacokinetics and pharmacodynamics of anticancer drugs, proteome and metaborome, anticancer effects and adverse drug reactions. | — |
Countries
Japan
Contacts
Public ContactYasutsuna Sasaki
Saitama Medical University, International Medical Center Medical Oncology
Outcome results
None listed